42 - References

References

Bipolar disorder CHAPTER 2 References

1. ECNP. Neuroscience-­based nomenclature (NbN). 2024; https://www.ecnp.eu/research-­innovation/nomenclature.
2. Cipriani A, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-­treatments meta-­analysis. Lancet 2011; 378:1306–­1315.
3. Goodwin GM, et  al. Evidence-­based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495–­553.
4. Chou JC, et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol 1999; 19:500–­505.
5. Small JG, et al. A placebo-­controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975; 132:1315–­1317.
6. Soares JC, et al. Adjunctive antipsychotic use in bipolar patients: an open 6-­month prospective study following an acute episode. J Affect Disord 1999; 56:1–­8.
7. Keck PE, Jr, et al. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59 Suppl 6:74–­81.
8. Tohen M, et al. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998; 59 Suppl 1:38–­48.
9. Zarate CA, Jr, et al. Double-­blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004; 161:169–­171.
10. Gigante AD, et al. Long-­acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs 2012; 26:403–­420.
11. Goikolea JM, et al. Lower rate of depressive switch following antimanic treatment with second-­generation antipsychotics versus haloperidol. J Affect Disord 2013; 144:191–­198.
12. Yildiz A, et al. A network meta-­analysis on comparative efficacy and all-­cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 2015; 45:299–­317.
13. Kishi T, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-­analysis of double-­blind randomized controlled trials. Mol Psychiatry 2022; 27:1136–­1144.
14. Baldessarini RJ, et al. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry 2019; 24:198–­217.
15. Yu CL, et al. Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia. BMJ Ment Health 2023; 26:e300546.
16. Ogawa Y, et al. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-­analysis of combination/augmentation therapy versus monotherapy. CNS Drugs 2014; 28:989–­1003.
17. Ashok AH, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 2017; 22:666–­679.
18. Jauhar S, et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 2017; 74:1206–­1213.
19. Taylor DM, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-­treatments meta-­analysis. Acta Psychiatr Scand 2014; 130:452–­469.
20. Yildiz A, et al. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-­analysis. Lancet Psychiatry 2023; 10:693–­705.
21. Kadakia A, et al. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-­analysis. BMC Psychiatry 2021; 21:249.
22. Martins-­Correia J, et al. Cariprazine in the acute treatment of unipolar and bipolar depression: a systematic review and meta-­analysis. J Affect Disord 2024; 362:297–­307.
23. Taylor MJ. Bipolar treatment efficacy. Lancet Psychiatry 2014; 1:418.
24. Miura T, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-­analysis. Lancet Psychiatry 2014; 1:351–­359.
25. McIntyre RS, et al. Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder. Bipolar Disord 2024; 26:442–­453.
26. Sachs G, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-­week placebo-­controlled study. J Psychopharmacol 2006; 20:536–­546.
27. Keck PE, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-­blind, placebo-­ and lithium-­ controlled study. J Affect Disord 2009; 112:36–­49.
28. Young AH, et al. Aripiprazole monotherapy in acute mania: 12-­week randomised placebo-­ and haloperidol-­controlled study. Br J Psychiatry 2009; 194:40–­48.
29. Vieta E, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/ lithium monotherapy: a placebo-­controlled study. Am J Psychiatry 2008; 165:1316–­1325.
30. Keck PE, Jr, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-­week, double-­blind study versus placebo. J Clin Psychiatry 2007; 68:1480–­1491.
31. Vieta E, et al. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-­week, open-­label extension following a 6-­week double-­blind study. Curr Med Res Opin 2010; 26:1485–­1496.
32. Shafti SS. Aripiprazole versus lithium in management of acute mania: a randomized clinical trial. East Asian Arch Psychiatry 2018; 28:80–­84.
33. Brown R, et al. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev 2013; 12:CD005000.
34. Calabrese JR, et al. Efficacy and safety of aripiprazole once-­monthly in the maintenance treatment of bipolar I disorder: a double-­blind, placebo-­controlled, 52-­week randomized withdrawal study. J Clin Psychiatry 2017; 78:324–­331.

304 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 2 35. McIntyre RS, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-­blind, placebo-­controlled trial. J Affect Disord 2010; 122:27–­38. 36. McIntyre RS, et al. Asenapine versus olanzapine in acute mania: a double-­blind extension study. Bipolar Disord 2009; 11:815–­826. 37. McIntyre RS, et al. Asenapine for long-­term treatment of bipolar disorder: a double-­blind 40-­week extension study. J Affect Disord 2010; 126:358–­365. 38. Szegedi A, et al. Randomized, double-­blind, placebo-­controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 2018; 175:71–­79. 39. Pillinger T, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-­analysis. Lancet Psychiatry 2020; 7:64–­77. 40. McIntyre RS, et al. Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. J Affect Disord 2019; 257:600–­606. 41. Zarate CA, Jr, et al. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56:411–­417. 42. Li XB, et al. Clozapine for treatment-­resistant bipolar disorder: a systematic review. Bipolar Disord 2015; 17:235–­247. 43. Loo LWJ, et al. Clozapine use for bipolar disorder: an Asian Psychotropic Prescription Patterns Consortium Study. J Clin Psychopharmacol 2023; 43:278–­282. 44. Loebel A, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-­blind, placebo-­controlled study. Am J Psychiatry 2014; 171:160–­168. 45. Loebel A, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-­ blind, placebo-­controlled study. Am J Psychiatry 2014; 171:169–­177. 46. Tohen M, et  al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156:702–­709. 47. Tohen M, et al. Efficacy of olanzapine in acute bipolar mania: a double-­blind, placebo-­controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57:841–­849. 48. Tohen M, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59:62–­69. 49. Tohen M, et al. Relapse prevention in bipolar I disorder: 18-­month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184:337–­345. 50. Tohen M, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008; 192:135–­143. 51. Sanger TM, et al. Long-­term olanzapine therapy in the treatment of bipolar I disorder: an open-­label continuation phase study. J Clin Psychiatry 2001; 62:273–­281. 52. Vieta E, et  al. Olanzapine as long-­term adjunctive therapy in treatment-­resistant bipolar disorder. J Clin Psychopharmacol 2001; 21:469–­473. 53. Tohen M, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-­month, randomized, double-­blind, controlled clinical trial. Am J Psychiatry 2005; 162:1281–­1290. 54. McKnight RF, et al. Lithium for acute mania. Cochrane Database Syst Rev 2019; 6:CD004048. 55. Corrao MM, et al. Olanzapine/samidorphan: a new combination treatment for schizophrenia and bipolar I disorder intended to reduce weight gain. CNS Drugs 2022; 36:605–­616. 56. Faden J, et al. Olanzapine-­samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder –­ what is it, and will it be used? Expert Rev Neurother 2022; 22:365–­376. 57. Ghaemi SN, et al. The use of quetiapine for treatment-­resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999; 11:137–­140. 58. Sachs G, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-­blind, placebo-­controlled study. Bipolar Disord 2004; 6:213–­223. 59. Altamura AC, et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-­month open label study. J Affect Disord 2003; 76:267–­271. 60. Young AH, et al. A randomised, placebo-­controlled 52-­week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry 2014; 15:96–­112. 61. Segal J, et  al. Risperidone compared with both lithium and haloperidol in mania: a double-­blind randomized controlled trial. Clin Neuropharmacol 1998; 21:176–­180. 62. Sachs GS, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-­blind, placebo-­ controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159:1146–­1154. 63. Vieta E, et al. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord 2002; 72:15–­19. 64. Quiroz JA, et al. Risperidone long-­acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68:156–­162. 65. Taylor DM, et al. Paliperidone palmitate: factors predicting continuation with treatment at 2 years. Eur Neuropsychopharmacol 2016; 26:2011–­2017. 66. Vieta E, et al. An open-­label study of amisulpride in the treatment of mania. J Clin Psychiatry 2005; 66:575–­578. 67. Vieta E, et al. Ziprasidone in the treatment of acute mania: a 12-­week, placebo-­controlled, haloperidol-­referenced study. J Psychopharmacol 2010; 24:547–­558. 68. Singh V, et al. An open trial of iloperidone for mixed episodes in bipolar disorder. J Clin Psychopharmacol 2017; 37:615–­619. 69. McIntyre RS, et  al. The efficacy of lumateperone in patients with bipolar depression with mixed features. J Clin Psychiatry 2023; 84:22m14739. 70. Calabrese JR, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-­controlled trial. Am J Psychiatry 2021; 178:1098–­1106.